서브메뉴
검색
Auxiliary System to Overcome Resistance of Therapeutic Monoclonal Antibody in Anti-cancer Treatment
Auxiliary System to Overcome Resistance of Therapeutic Monoclonal Antibody in Anti-cancer Treatment
상세정보
- 자료유형
- 학위논문 서양
- 최종처리일시
- 20250211152002
- ISBN
- 9798382829524
- DDC
- 610
- 저자명
- Qi, Tong.
- 서명/저자
- Auxiliary System to Overcome Resistance of Therapeutic Monoclonal Antibody in Anti-cancer Treatment
- 발행사항
- [Sl] : University of California, Los Angeles, 2024
- 발행사항
- Ann Arbor : ProQuest Dissertations & Theses, 2024
- 형태사항
- 109 p
- 주기사항
- Source: Dissertations Abstracts International, Volume: 85-12, Section: A.
- 주기사항
- Advisor: Lu, Yunfeng.
- 학위논문주기
- Thesis (Ph.D.)--University of California, Los Angeles, 2024.
- 초록/해제
- 요약Rituximab, an anti-CD20 monoclonal antibody, has revolutionized the treatment for lymphoma, particularly B-cell non-Hodgkin lymphoma; the therapeutic efficacy, however, is limited by its temporary activity, non-ideal biodistribution, and heterogeneity of the cancer cells. In this dissertation research, two auxiliary systems were designed to improve the therapeutic efficacy of rituximab. The first system involves a novel combination treatment for non-Hodgkin lymphoma using rituximab and a whole cell-based therapeutic cancer vaccine, which effectively elicited a specific immune response, established immune memory, offered both immediate tumor killing and sustained protection from relapse of cancer. The second system involves a design of novel protein delivery systems that target lymph nodes, which help eliminate circulating cancer cells within the lymph nodes, block metastatic pathways, and reduce cancer metastasis and relapse. The strategies described in this dissertation research can be extended to other monoclonal antibody therapeutics and cancer therapies beyond non-Hodgkin lymphoma therapeutics, providing a platform towards more effective cancer therapy.
- 일반주제명
- Biomedical engineering
- 일반주제명
- Cellular biology
- 일반주제명
- Oncology
- 일반주제명
- Therapy
- 일반주제명
- Immunology
- 키워드
- Rituximab
- 키워드
- Lymphoma
- 키워드
- Cancer cells
- 기타저자
- University of California, Los Angeles Chemical Engineering 0294
- 기본자료저록
- Dissertations Abstracts International. 85-12A.
- 전자적 위치 및 접속
- 로그인 후 원문을 볼 수 있습니다.
MARC
008250123s2024 us c eng d■001000017162348
■00520250211152002
■006m o d
■007cr#unu||||||||
■020 ▼a9798382829524
■035 ▼a(MiAaPQ)AAI31330073
■040 ▼aMiAaPQ▼cMiAaPQ
■0820 ▼a610
■1001 ▼aQi, Tong.
■24510▼aAuxiliary System to Overcome Resistance of Therapeutic Monoclonal Antibody in Anti-cancer Treatment
■260 ▼a[Sl]▼bUniversity of California, Los Angeles▼c2024
■260 1▼aAnn Arbor▼bProQuest Dissertations & Theses▼c2024
■300 ▼a109 p
■500 ▼aSource: Dissertations Abstracts International, Volume: 85-12, Section: A.
■500 ▼aAdvisor: Lu, Yunfeng.
■5021 ▼aThesis (Ph.D.)--University of California, Los Angeles, 2024.
■520 ▼aRituximab, an anti-CD20 monoclonal antibody, has revolutionized the treatment for lymphoma, particularly B-cell non-Hodgkin lymphoma; the therapeutic efficacy, however, is limited by its temporary activity, non-ideal biodistribution, and heterogeneity of the cancer cells. In this dissertation research, two auxiliary systems were designed to improve the therapeutic efficacy of rituximab. The first system involves a novel combination treatment for non-Hodgkin lymphoma using rituximab and a whole cell-based therapeutic cancer vaccine, which effectively elicited a specific immune response, established immune memory, offered both immediate tumor killing and sustained protection from relapse of cancer. The second system involves a design of novel protein delivery systems that target lymph nodes, which help eliminate circulating cancer cells within the lymph nodes, block metastatic pathways, and reduce cancer metastasis and relapse. The strategies described in this dissertation research can be extended to other monoclonal antibody therapeutics and cancer therapies beyond non-Hodgkin lymphoma therapeutics, providing a platform towards more effective cancer therapy.
■590 ▼aSchool code: 0031.
■650 4▼aBiomedical engineering
■650 4▼aCellular biology
■650 4▼aOncology
■650 4▼aTherapy
■650 4▼aImmunology
■653 ▼aRituximab
■653 ▼aLymphoma
■653 ▼aCancer cells
■653 ▼aMonoclonal antibody therapeutics
■653 ▼aCancer metastasis
■690 ▼a0541
■690 ▼a0379
■690 ▼a0992
■690 ▼a0982
■690 ▼a0212
■71020▼aUniversity of California, Los Angeles▼bChemical Engineering 0294.
■7730 ▼tDissertations Abstracts International▼g85-12A.
■790 ▼a0031
■791 ▼aPh.D.
■792 ▼a2024
■793 ▼aEnglish
■85640▼uhttp://www.riss.kr/pdu/ddodLink.do?id=T17162348▼nKERIS▼z이 자료의 원문은 한국교육학술정보원에서 제공합니다.
